Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, has announced its participation in two upcoming investor conferences.

The company will participate in the TD Cowen 45th Annual Health Care Conference, where CEO Marino Garcia will conduct a fireside chat on March 5, 2025, at 11:50 a.m. ET in Boston. The presentation will be available via webcast on the company's website under the Investors section.

Additionally, Ryan Savitz, Chief Financial Officer and Chief Business Officer, will host one-on-one investor meetings at the Jefferies Biotech on the Bay Summit on March 12, 2025, in Miami.

News Market Reaction

-6.32%

1 alert

-6.32% News Effect

On the day this news was published, DNTH declined 6.32%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the following investor conferences:

• TD Cowen 45th Annual Health Care Conference – Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 5 at 11:50 a.m. ET and host one-on-one meetings with investors in Boston. A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
  
  
• Jefferies Biotech on the Bay Summit – Ryan Savitz, Chief Financial Officer and Chief Business Officer, will host one-on-one investor meetings on Wednesday, March 12 in Miami
  

About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

When is Dianthus Therapeutics (DNTH) presenting at the TD Cowen Healthcare Conference 2025?

Dianthus Therapeutics will present on March 5, 2025, at 11:50 a.m. ET during the TD Cowen 45th Annual Health Care Conference in Boston.

Where can investors watch the DNTH TD Cowen conference presentation?

The presentation webcast will be available under the 'News and Events' section in the Investors portion of the Dianthus Therapeutics website.

Which executives from DNTH are participating in the March 2025 investor conferences?

CEO Marino Garcia will present at the TD Cowen conference, while CFO/CBO Ryan Savitz will attend the Jefferies Biotech summit.

What type of therapeutic products is DNTH developing?

Dianthus Therapeutics is developing next-generation antibody complement therapeutics aimed at treating severe autoimmune diseases.

When and where is DNTH participating in the Jefferies Biotech on the Bay Summit?

Dianthus Therapeutics will participate on March 12, 2025, in Miami, hosting one-on-one investor meetings.